Sang Meixiang, Wu Xiaohua, Fan Xiaojie, Lian Yishui, Sang Meijie
a Department of Obstetrics and Gynecology , Bethune International Peace Hospital , Shijiazhuang , People's Republic of China.
b Research Center, The Fourth Hospital of Hebei Medical University , Shijiazhuang , People's Republic of China , and.
Gynecol Endocrinol. 2017 Jun;33(6):480-484. doi: 10.1080/09513590.2017.1291611. Epub 2017 Feb 28.
The aim of our study is to investigate the expression pattern and prognostic significance of melanoma-associated antigens-A (MAGE-A) family in primary epithelial ovarian cancer (EOC) patients.
The expression of MAGE-A family members, including MAGE-A1, -A2, -A3, -A4, -A6, -A10 and -A12 was immunohistochemically detected in 82 cases of primary EOC and 10 cases of pericarcinoma ovarian tissues. The association between MAGE-A family expression and the clinicopathological parameters as well as the prognosis of primary EOC patients was analyzed.
MAGE-A family expressed in 48.8% of primary EOC tissues, but not expressed in pericarcinoma ovarian tissues. MAGE-A expression was associated with the pathological types, FIGO stage, and pre-operative serum CA125 level. Overall survival of EOC patients with positive MAGE-A family expression was significantly shorter than those patients with negative MAGE-A expression. Multivariate analysis showed that although MAGE-A family expression can affect the overall survival, it was not an independent prognostic marker for EOC patients.
Molecular assessment of MAGE-A family members could be helpful to improve the prognostic evaluation and to provide a new potential therapeutic target for primary EOC patients.
本研究旨在探讨黑色素瘤相关抗原-A(MAGE-A)家族在原发性上皮性卵巢癌(EOC)患者中的表达模式及预后意义。
采用免疫组织化学方法检测82例原发性EOC患者及10例癌旁卵巢组织中MAGE-A家族成员,包括MAGE-A1、-A2、-A3、-A4、-A6、-A10和-A12的表达情况。分析MAGE-A家族表达与原发性EOC患者临床病理参数及预后的相关性。
MAGE-A家族在48.8%的原发性EOC组织中表达,而在癌旁卵巢组织中不表达。MAGE-A表达与病理类型、国际妇产科联盟(FIGO)分期及术前血清CA125水平相关。MAGE-A家族表达阳性的EOC患者总生存期显著短于MAGE-A表达阴性的患者。多因素分析显示,虽然MAGE-A家族表达可影响总生存期,但它不是EOC患者的独立预后标志物。
对MAGE-A家族成员进行分子评估可能有助于改善预后评估,并为原发性EOC患者提供新的潜在治疗靶点。